Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron's COVID-19 antibody drug may be less effective against Omicron

11/30/2021 | 06:24am EST

Nov 30 (Reuters) - Regeneron Pharmaceuticals Inc's COVID-19 antibody drug could be less effective against Omicron, it said on Tuesday, adding to fears about the efficacy of existing treatments after Moderna's top boss raised similar concerns about the company's vaccine.

Global markets tumbled after comments from Moderna's chief executive officer rekindled worries that the variant may weigh on a nascent global economic recovery.

Based on its study of Omicron's individual mutations, "there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity", Regeneron said, adding that the analysis included its COVID-19 antibody cocktail, REGEN-COV.

The company said it was doing further study to quantify the potential impact using the variant's genetic sequence.

One of the antibodies used in the treatment will likely take a hit, the other less so, CEO Len Schleifer said in a CNBC interview.

"Just like vaccines will have to adapt, we're probably going to have to constantly adapt our monoclonals."

Eli Lilly and Co, which makes a similar monoclonal antibody treatment, is also working to understand neutralization activity of its therapies on Omicron, the company told Reuters in an e-mailed statement.

Regeneron shares fell about 3% in morning trading, while those of Lilly shed 2.5%.

Rival Vir Biotechnology Inc said based on the Omicron sequence its antibody therapy, sotrovimab, will likely maintain potency against the variant.

The company is "working to confirm this in the lab as a matter of urgency", it added.

Gilead Inc said it believed its intravenous therapy, Remdesivir, currently the only antiviral approved for treating COVID-19, will continue to be effective against currently identified variants, including Omicron

The U.S. Food & Drug Administration said on Tuesday it was evaluating the effectiveness of authorized COVID-19 vaccines against Omicron and was expecting to have more information in the next few weeks.

(Reporting by Manas Mishra and Mrinalika Roy in Bengaluru; Editing by Shounak Dasgupta, Sriraj Kalluvila and Anil D'Silva)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES, INC. 1.03% 68.51 Delayed Quote.-5.65%
MODERNA, INC. -4.45% 160.07 Delayed Quote.-36.98%
REGENERON PHARMACEUTICALS 1.14% 621.4 Delayed Quote.-1.60%
VIR BIOTECHNOLOGY, INC. 0.97% 33.46 Delayed Quote.-20.09%
All news about REGENERON PHARMACEUTICALS
01/21GSK, Vir ramping up U.S. output of COVID antibody drug
RE
01/21Regeneron - FORTY ACCOMPLISHED YOUNG SCIENTISTS NAMED FINALISTS IN THE 2022 REGENERON S..
AQ
01/20Forty Accomplished Young Scientists Named Finalists in the 2022 Regeneron Science Talen..
PR
01/20Fda accepts for review libtayo in combination with chemotherapy for first-line treatmen..
AQ
01/19Regeneron Says US FDA Accepts for Review its Supplemental BLA for Libtayo in Combinatio..
MT
01/19Regeneron Says FDA to Review Libtayo/Chemotherapy Combo in First-Line NSCLC Treatment
DJ
01/19FDA Accepts for Review Libtayo« (cemiplimab-rwlc) in Combination with Chemotherapy for ..
PR
01/19FDA Accepts for Review Libtayo« (cemiplimab-rwlc) in Combination with Chemotherapy for ..
CI
01/19Sanofi, Regeneron Say Dupixent Significantly Reduces Itching in Prurigo Nodularis Patie..
MT
01/19Sanofi-Regeneron's Dermatitis Drug Lowers Itch, Skin Lesions In Late-Stage Trial
MT
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Financials (USD)
Sales 2021 15 548 M - -
Net income 2021 7 971 M - -
Net cash 2021 4 180 M - -
P/E ratio 2021 8,82x
Yield 2021 -
Capitalization 64 971 M 64 971 M -
EV / Sales 2021 3,91x
EV / Sales 2022 4,33x
Nbr of Employees 9 766
Free-Float -
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 621,40 $
Average target price 697,73 $
Spread / Average Target 12,3%
EPS Revisions
Managers and Directors
Leonard S. Schleifer Chairman, Co-President & CEO
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl SVP-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
REGENERON PHARMACEUTICALS-1.60%64 971
GILEAD SCIENCES, INC.-5.65%85 938
VERTEX PHARMACEUTICALS3.86%57 990
WUXI APPTEC CO., LTD.-9.18%49 645
BIONTECH SE-42.79%35 624
BEIGENE, LTD.-7.19%25 835